TUESDAY, Feb. 6, 2018 (HealthDay News) — A substantial proportion of individuals with pancreatic cancer and a history of other hereditary breast and ovarian cancer (HBOC)- or Lynch syndrome (LS)-related cancers have mutations in a prostate cancer susceptibility gene, according to a study published online Jan. 23 in Cancer.
Beth Dudley, M.P.H., from the University of Pittsburgh, and colleagues used a pancreatic disease registry to identify 149 patients with pancreatic cancer and a history of cancer. For individuals who had not previously had a mutation identified through clinical testing or had undergone clinical multigene panel testing with no mutations detected, multigene panel testing was performed with banked DNA, if available.
The researchers found that 22 of 124 individuals with pancreatic cancer and another HBOC- or LS-related cancer (18 percent) had a mutation identified in a pancreatic cancer susceptibility gene. The mutation prevalence increased to 23 percent (21 of 93) when prostate cancer was excluded. Mutation carriers were significantly more likely to have had more than one previous cancer diagnosis, to have had clinical genetic testing, and to have met National Comprehensive Cancer Network (NCCN) genetic testing criteria. However, nearly one-quarter of mutation carriers (23 percent) did not meet NCCN HBOC or LS testing guidelines based on either their personal cancer history or reported cancer history in first-degree relatives.
“At least 18 percent of individuals with pancreatic cancer and a personal history of other HBOC- or LS-related cancers carry mutations in a pancreatic cancer susceptibility gene based on our data, suggesting that criteria for genetic testing in individuals with pancreatic cancer should include consideration of previous cancer history,” conclude the authors.
Several authors disclosed ties to biotechnology and genetic testing companies.
Copyright © 2018 HealthDay. All rights reserved.